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Introduction {#jah32000-sec-0004}
============

Thirty years ago, Murry et al[1](#jah32000-bib-0001){ref-type="ref"} first described ischemic preconditioning (IPC) after observing that anesthetized dogs subjected to prolonged circumflex coronary artery occlusion and reperfusion demonstrated a marked reduction of myocardial infarct size when exposed to 4 brief episodes of ischemia in the circumflex territory separated by 5 minutes of reperfusion prior to the prolonged occlusion. Remote IPC (RIPC) evolved from the same in vivo canine heart model where ischemia‐reperfusion injury could be attenuated in the left anterior descending coronary artery distribution after application of occlusion and reperfusion to the circumflex coronary artery.[2](#jah32000-bib-0002){ref-type="ref"} With this finding, Przyklenk et al[2](#jah32000-bib-0002){ref-type="ref"} concluded that protective mediators induced by ischemia could be transferred to distant, "regional" cardiomyocytes. Subsequent studies demonstrated that protection against ischemia‐reperfusion injury in humans could be extended to distant organs, such as the kidney and brain.[3](#jah32000-bib-0003){ref-type="ref"}, [4](#jah32000-bib-0004){ref-type="ref"} The discovery that protection could be conferred by ischemia‐reperfusion cycles in distant skeletal muscle elicited invasively by rapid stimulation of the gastrocnemius in rabbits[5](#jah32000-bib-0005){ref-type="ref"} and noninvasively by a tourniquet in humans[6](#jah32000-bib-0006){ref-type="ref"} spurred widespread clinical interest.

Given that cardiac surgery has the potential for ischemia and reperfusion injury to the heart, kidney and brain,[7](#jah32000-bib-0007){ref-type="ref"}, [8](#jah32000-bib-0008){ref-type="ref"}, [9](#jah32000-bib-0009){ref-type="ref"} RIPC has long been viewed as an attractive approach to mitigate the deleterious clinical consequences of these events. Prior studies have shown that RIPC before cardiac surgery results in reductions in biomarkers of renal and cardiac injury.[10](#jah32000-bib-0010){ref-type="ref"}, [11](#jah32000-bib-0011){ref-type="ref"} However, randomized controlled trials (RCTs) of RIPC evaluating clinical cardiovascular and renal outcomes as well as overall mortality have not shown benefit.[12](#jah32000-bib-0012){ref-type="ref"}, [13](#jah32000-bib-0013){ref-type="ref"} Many of these trials utilized propofol anesthesia, which has been shown to negatively impact the benefits of RIPC.[14](#jah32000-bib-0014){ref-type="ref"} With the recent publication of the two largest trials of RIPC to date,[15](#jah32000-bib-0015){ref-type="ref"}, [16](#jah32000-bib-0016){ref-type="ref"} we performed an updated meta‐analysis of RCTs to better evaluate the clinical merit of this intervention.

Methods {#jah32000-sec-0005}
=======

Study Selection {#jah32000-sec-0006}
---------------

A systematic search of published studies in any language in the PubMed, Cochrane, EMBASE, and Web of Science databases from 1970 to December 13, 2015, was performed independently by two authors (V.P. and I.B.). Search terms included *remote ischemic preconditioning, cardiac surgery, kidney injury*, and *renal failure,* as well as combinations of these terms. A filter for RCTs was used. Bibliographies of retrieved articles and prior reviews on the subject were searched for other relevant studies.

For inclusion, studies were required to be prospective randomized trials of preoperative RIPC or a sham procedure in patients undergoing cardiac surgery performed on cardiopulmonary bypass. In addition, studies had to report at least one clinical end point of interest as an outcome and enroll more than 50 patients. Patient characteristics, study design, and outcomes were systematically reviewed and recorded independently by 3 authors (B.P., I.B., and V.P.). Disagreements were resolved by consensus.

The methodological quality of each trial was evaluated using standard criteria: method of randomization; allocation concealment; patient, investigator, and outcome assessor blinding; selective outcome reporting; incomplete outcome ascertainment; and other potential sources of bias as recommended by the Cochrane Collaboration.[17](#jah32000-bib-0017){ref-type="ref"} The Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) approach for evaluating RCTs was applied.[18](#jah32000-bib-0018){ref-type="ref"}

The following clinical end points were analyzed: all‐cause mortality, acute kidney injury (AKI), myocardial infarction (MI), cerebrovascular accident (CVA), hospital length of stay (LOS), and intensive care unit (ICU) LOS. Discrete working definitions of AKI were reclassified as stage I, II, or III based on previous definitions described by the Acute Kidney Injury Advisory Group.[19](#jah32000-bib-0019){ref-type="ref"} Other end point definitions were those used in the individual trials and are summarized in Table [1](#jah32000-tbl-0001){ref-type="table-wrap"}.[20](#jah32000-bib-0020){ref-type="ref"}, [21](#jah32000-bib-0021){ref-type="ref"}, [22](#jah32000-bib-0022){ref-type="ref"}, [23](#jah32000-bib-0023){ref-type="ref"}, [24](#jah32000-bib-0024){ref-type="ref"}, [25](#jah32000-bib-0025){ref-type="ref"}, [26](#jah32000-bib-0026){ref-type="ref"}, [27](#jah32000-bib-0027){ref-type="ref"}, [28](#jah32000-bib-0028){ref-type="ref"}, [29](#jah32000-bib-0029){ref-type="ref"}, [30](#jah32000-bib-0030){ref-type="ref"}, [31](#jah32000-bib-0031){ref-type="ref"}, [32](#jah32000-bib-0032){ref-type="ref"}, [33](#jah32000-bib-0033){ref-type="ref"}

###### 

End Point Definitions

  Trial                                                             All‐Cause Mortality                                              AKI                                                            MI                                                                                                                                                                                                                                                                                  Stroke                                                                                                                                                                                              ICU LOS                                                                  Hospital LOS
  ----------------------------------------------------------------- ---------------------------------------------------------------- -------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------ -------------------------------------
  Rahman et al, 2010[20](#jah32000-bib-0020){ref-type="ref"}        N/A                                                              \>0.5 mg/dL^−1^ creatinine rise on day 4 postoperatively       N/A                                                                                                                                                                                                                                                                                 N/A                                                                                                                                                                                                 Postoperative ICU stay in days                                           Postoperative hospital stay in days
  Venugopal et al, 2010[21](#jah32000-bib-0021){ref-type="ref"}     Death from any cause within 30 d                                 AKIN criteria in first 72 h postoperatively                    N/A                                                                                                                                                                                                                                                                                 N/A                                                                                                                                                                                                 N/A                                                                      Postoperative hospital stay in days
  Li et al, 2010[22](#jah32000-bib-0022){ref-type="ref"}            N/A                                                              N/A                                                            N/A                                                                                                                                                                                                                                                                                 N/A                                                                                                                                                                                                 Postoperative ICU stay in hours[a](#jah32000-note-0003){ref-type="fn"}   Postoperative hospital stay in days
  Karuppasamy et al, 2011[23](#jah32000-bib-0023){ref-type="ref"}   N/A                                                              N/A                                                            N/A                                                                                                                                                                                                                                                                                 N/A                                                                                                                                                                                                 Postoperative ICU stay in hours[a](#jah32000-note-0003){ref-type="fn"}   Postoperative hospital stay in days
  Wu et al, 2011[24](#jah32000-bib-0024){ref-type="ref"}            N/A                                                              N/A                                                            N/A                                                                                                                                                                                                                                                                                 N/A                                                                                                                                                                                                 Postoperative ICU stay in hours[a](#jah32000-note-0003){ref-type="fn"}   Postoperative hospital stay in days
  Choi et al, 2011[25](#jah32000-bib-0025){ref-type="ref"}          N/A                                                              AKIN criteria in first 48 h postoperatively                    N/A                                                                                                                                                                                                                                                                                 N/A                                                                                                                                                                                                 Postoperative ICU stay in days                                           Postoperative hospital stay in days
  Zimmerman et al, 2011[3](#jah32000-bib-0003){ref-type="ref"}      Death from any cause within the index stay                       AKIN criteria in first 48 h postoperatively                    N/A                                                                                                                                                                                                                                                                                 N/A                                                                                                                                                                                                 N/A                                                                      Postoperative hospital stay in days
  Lucchinetti et al, 2012[26](#jah32000-bib-0026){ref-type="ref"}   Death from any cause within the follow‐up period (6 mo)          N/A                                                            Perioperative increase in cTnI to 5× the 99th percentile reference range with new pathological Q waves, LBBB, or new angiographic occlusion. Postoperative increase in cTnI to 2× reference range with evidence of ischemia                                                         N/A                                                                                                                                                                                                 N/A                                                                      N/A
  Xie et al, 2012[27](#jah32000-bib-0027){ref-type="ref"}           Death from any cause within the follow‐up period (3‐39 mo)       N/A                                                            N/A                                                                                                                                                                                                                                                                                 N/A                                                                                                                                                                                                 N/A                                                                      N/A
  Young et al, 2012[13](#jah32000-bib-0013){ref-type="ref"}         N/A                                                              RIFLE criteria for index stay                                  N/A                                                                                                                                                                                                                                                                                 N/A                                                                                                                                                                                                 N/A                                                                      N/A
  Lomivorotov et al, 2012[41](#jah32000-bib-0041){ref-type="ref"}   Death from any cause within the follow‐up period (30 d)          N/A                                                            N/A                                                                                                                                                                                                                                                                                 N/A                                                                                                                                                                                                 Postoperative ICU stay in days                                           N/A
  Meybohm et al, 2013[28](#jah32000-bib-0028){ref-type="ref"}       N/A                                                              AKIN criteria in first 48 h postoperatively                    N/A                                                                                                                                                                                                                                                                                 N/A                                                                                                                                                                                                 Postoperative ICU stay in hours[a](#jah32000-note-0003){ref-type="fn"}   Postoperative hospital stay in days
  Thielmann et al, 2013[29](#jah32000-bib-0029){ref-type="ref"}     Death from any cause within the follow‐up period (4+ y)          N/A                                                            Perioperative increase in cTnI to 5× the 99th percentile reference range with new pathological Q waves, LBBB, or new angiographic occlusion. Postoperative increase in cTnI to 2× reference range with evidence of ischemia                                                         Any embolic event after immediate postoperative period; a neurological event resulting in a new deficit; any neurological event lasting \>24 h unless a cerebral lesion was visualized on imaging   Postoperative ICU stay in days                                           Postoperative hospital stay in days
  Gallagher et al, 2015[30](#jah32000-bib-0030){ref-type="ref"}     Death from any cause within 30 d                                 AKIN criteria in first 48 h postoperatively                    N/A                                                                                                                                                                                                                                                                                 N/A                                                                                                                                                                                                 Postoperative ICU stay in hours[a](#jah32000-note-0003){ref-type="fn"}   Postoperative hospital stay in days
  Ahmad et al, 2014[12](#jah32000-bib-0012){ref-type="ref"}         Death from any cause within the index hospital stay              N/A                                                            N/A                                                                                                                                                                                                                                                                                 N/A                                                                                                                                                                                                 N/A                                                                      N/A
  Slagsvold et al, 2014[31](#jah32000-bib-0031){ref-type="ref"}     Death from any cause within 30 d                                 N/A                                                            N/A                                                                                                                                                                                                                                                                                 N/A                                                                                                                                                                                                 N/A                                                                      N/A
  Candilio et al, 2015[32](#jah32000-bib-0032){ref-type="ref"}      Death from any cause within 6 wk                                 RIFLE criteria in first 72 h postoperatively                   Myocardial infarction (not defined) by 6 wk                                                                                                                                                                                                                                         Stroke (not defined) by 6 wk                                                                                                                                                                        Postoperative ICU stay in days                                           Postoperative hospital stay in days
  Zarbock et al, 2015[11](#jah32000-bib-0011){ref-type="ref"}       Death from any cause within 30 d                                 KDIGO criteria in first 72 h postoperatively                   Perioperative increase in cTnI to 5× the 99th percentile of reference range with new pathological Q waves, LBBB, or new angiographic occlusion. Postoperative increase in cTnI to 2× reference range with evidence of ischemia                                                      Any embolic event after immediate postoperative period; a neurological event resulting in a new deficit; any neurological event lasting \>24 h unless a cerebral lesion was visualized on imaging   Postoperative ICU stay in days                                           Postoperative hospital stay in days
  Pinaud et al, 2016[33](#jah32000-bib-0033){ref-type="ref"}        N/A                                                              AKIN criteria in first 72 h postoperatively                    N/A                                                                                                                                                                                                                                                                                 N/A                                                                                                                                                                                                 Postoperative ICU stay in hours[a](#jah32000-note-0003){ref-type="fn"}   N/A
  Meybohm et al, 2015[16](#jah32000-bib-0016){ref-type="ref"}       Death from any cause within index hospital stay (maximum 14 d)   Increase in serum creatinine by a factor of ≥2 from baseline   Biomarker values over 5× the 99th percentile of reference range with pathological Q waves or new LBBB in first 72 h. Standard clinical criteria for MI from 72 h onward. Ischemia by echocardiography or angiography. MI diagnosed at autopsy                                       New, temporary, or permanent focal or global neurological deficit. Evidence of stroke at autopsy                                                                                                    N/A                                                                      N/A
  Hausenloy et al, 2015[15](#jah32000-bib-0015){ref-type="ref"}     Death from any cause within 12 mo                                KDIGO criteria in first 72 h postoperatively                   Biomarker values \>10× the 99th percentile of reference range when associated with new pathological Q waves, new LBBB, or angiographically documented occlusion in the first 72 h postoperatively or biomarker value \>100× the 99th percentile in the first 72 h postoperatively   Focal neurological deficit of cerebrovascular cause persisting beyond 24 h or interrupted by death within 24 h                                                                                      Postoperative ICU stay in days                                           Postoperative hospital stay in days

AKIN indicates acute kidney injury network; cTnI, cardiac troponin I; ICU, intensive care unit; KDIGO, Kidney Disease: Improving Global Outcomes; LBBB, left bundle branch block; LOS, length of stay; MI, myocardial infarction; N/A, not applicable; RIFLE, risk, injury, failure, loss, end‐stage.

Hours were divided by 24 for unit of measurement uniformity.

Statistical Analysis {#jah32000-sec-0007}
--------------------

Because patient‐level data from each trial were not available, a meta‐analysis of summary statistics from individual trials was performed. Data from each trial were analyzed on an intention‐to‐treat basis according to the recommendations of the Cochrane Collaboration and the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses statement.[34](#jah32000-bib-0034){ref-type="ref"} Trial results for each end point were summarized with risk ratios (RRs) and standardized mean differences as the measures of effect. RRs were employed because accurate time‐to‐event data were not available in all trials. Summary RRs or standardized mean differences and 95% CIs were calculated using a random‐effects model for combining results across studies, which incorporates between‐ and within‐study variance and provides a more conservative summary. A random‐effects model was preferred because heterogeneity across patient characteristics and clinical trial design would be unlikely to result in a consistent treatment effect across trials.[35](#jah32000-bib-0035){ref-type="ref"} When no events were observed within a treatment group, a 0.5 correction factor was added to all values of that end point for calculation of the RR and its variance.[36](#jah32000-bib-0036){ref-type="ref"}, [37](#jah32000-bib-0037){ref-type="ref"} To determine whether there was heterogeneity between individual trials, we assessed the Q statistic (a weighted index of effect estimate differences across studies assuming a χ^2^ distribution) and *I* ^2^ statistic (\[Q−*df*\]/Q×100). Because the *I* ^2^ value quantifies heterogeneity on a scale of 0% to 100% and represents the extent of inconsistency among trial results rather than a sampling error independent of the number of studies, an *I* ^2^ of ≥75% was considered representative of high heterogeneity.[38](#jah32000-bib-0038){ref-type="ref"} To assess for publication bias, funnel plots were evaluated by visual inspection and confirmed by Egger\'s test.[39](#jah32000-bib-0039){ref-type="ref"} If analysis yielded plot asymmetry, Duval and Tweedie\'s trim and fill method, a quantitative assessment of publication bias, was performed.[40](#jah32000-bib-0040){ref-type="ref"}

Heterogeneity was explored in subgroup analyses by study quality (high versus low), intraoperative propofol use, additive European System for Cardiac Operative Risk Evaluation (EuroSCORE), and preoperative potassium‐ATP (K‐ATP) antagonist use. Unless an anesthetic regimen without propofol was detailed, it was assumed that propofol was administered. In the event of protocol ambiguity, primary authors were contacted for clarification. In trials that did not exclude diabetic patients, it was assumed that K‐ATP antagonists were used unless specifically prohibited preoperatively. Sensitivity analyses were performed for each outcome to determine whether any single study disproportionately influenced the pooled estimate by excluding individual trials one at a time and recalculating the combined RR or standardized mean difference for the remaining studies. *P*\<0.05 was considered statistically significant and all tests were 2‐sided. Statistical analyses were performed with Comprehensive Meta‐Analysis (version 2) software (Biostat, Englewood, NJ).

Results {#jah32000-sec-0008}
=======

Literature Search {#jah32000-sec-0009}
-----------------

The electronic search yielded 833 citations that were screened by reviewing the title or abstract with subsequent removal of duplicates. Of these, 45 articles were reviewed in full and 21 studies were included for analysis (Figure [1](#jah32000-fig-0001){ref-type="fig"}). Characteristics of the studies are listed in Table [2](#jah32000-tbl-0002){ref-type="table-wrap"}. Eight studies tested RIPC in patients undergoing isolated coronary artery bypass grafting (CABG),[12](#jah32000-bib-0012){ref-type="ref"}, [20](#jah32000-bib-0020){ref-type="ref"}, [21](#jah32000-bib-0021){ref-type="ref"}, [23](#jah32000-bib-0023){ref-type="ref"}, [26](#jah32000-bib-0026){ref-type="ref"}, [29](#jah32000-bib-0029){ref-type="ref"}, [31](#jah32000-bib-0031){ref-type="ref"}, [41](#jah32000-bib-0041){ref-type="ref"} four studies in patients undergoing isolated valve surgery,[22](#jah32000-bib-0022){ref-type="ref"}, [24](#jah32000-bib-0024){ref-type="ref"}, [27](#jah32000-bib-0027){ref-type="ref"}, [33](#jah32000-bib-0033){ref-type="ref"} and the remaining 9 in patients undergoing any cardiac surgery.[1](#jah32000-note-1001){ref-type="fn"} One study included additional perconditioning, the application of short periods of ischemia and reperfusion at a distant site delivered during target organ ischemia; only data from the preconditioning intervention and the sham procedure were included.[22](#jah32000-bib-0022){ref-type="ref"}

![Study selection. Flow diagram depicts study selection for inclusion in the meta‐analysis according to the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses.[34](#jah32000-bib-0034){ref-type="ref"} RIPC indicates remote ischemic preconditioning.](JAH3-6-e004666-g001){#jah32000-fig-0001}

###### 

Characteristics of Trials

  Study                                                             Country, Enrollment Years   No. of Patients Enrolled (RIPC/Sham)   Mean or Median Age (RIPC/Sham)   Male (RIPC/Sham), %   Inclusion Criteria                                                                          Primary End Point                                                                                   CABG, Valve Surgery, or Mixed   Propofol Use   K‐ATP Antagonist Use   Preconditioning Site and Duration (Cycles×min)
  ----------------------------------------------------------------- --------------------------- -------------------------------------- -------------------------------- --------------------- ------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------- ------------------------------- -------------- ---------------------- ------------------------------------------------
  Rahman et al, 2010[20](#jah32000-bib-0020){ref-type="ref"}        UK, 2007--2009              162 (80/82)                            63/65                            89.0/88.0             Isolated first‐time multivessel CABG                                                        Troponin AUC at 48 h                                                                                CABG                            Yes            No                     UL, 3×5
  Venugopal et al, 2010[21](#jah32000-bib-0021){ref-type="ref"}     UK, 2006--2008              78 (38/40)                             64.0/66.0                        79.0/85.0             Elective CABG                                                                               Perioperative AKI in first 72 h                                                                     CABG                            Unknown        No                     UL, 3×5
  Li et al, 2010[22](#jah32000-bib-0022){ref-type="ref"}            China, 2009                 53 (26/27)                             45.8/42.3                        30.0/50.0             Age 18 to 65 y, rheumatic heart valve disease                                               Troponin release at 30 min and 4, 12, and 72 h after declamping                                     Valve replacement               Yes            No                     LL, 4×4
  Karuppasamy et al, 2011[23](#jah32000-bib-0023){ref-type="ref"}   UK, 2008--2009              54 (27/27)                             66.9/67.3                        81.0/85.0             Elective CABG                                                                               Troponin release at 6, 12, 24, and 48 h postoperatively                                             CABG                            Yes            No                     UL, 3×5
  Wu et al, 2011[24](#jah32000-bib-0024){ref-type="ref"}            Japan, 2009--2010           75 (50/25)                             46.2/43.6                        40.0/28.0             Age 18 to 60 y, mitral valve replacement                                                    Postoperative inotrope requirement, ICU LOS, hospital LOS                                           Valve replacement               Unknown        No                     UL, 3×5
  Choi et al, 2011[25](#jah32000-bib-0025){ref-type="ref"}          South Korea, 2008--2009     76 (38/38)                             57.0/60.0                        39.5/39.5             Elective, complex valvular heart surgery                                                    Postoperative biomarkers of renal injury and incidence of AKI                                       Mixed                           No             No                     LL, 3×10
  Zimmerman et al, 2011[3](#jah32000-bib-0003){ref-type="ref"}      US, 2008--2009              118 (59/59)                            62.0/65.0                        69.0/68.0             Elective cardiac surgery on CPB                                                             Postoperative AKI                                                                                   Mixed                           No             Yes                    LL, 3×5
  Lucchinetti et al, 2012[26](#jah32000-bib-0026){ref-type="ref"}   Canada, 2008--2010          55 (27/28)                             59.0/62.0                        96.0/86.0             Elective CABG, age 50 to 85 y                                                               Postoperative high‐sensitivity troponin release                                                     CABG                            Yes            No                     LL, 4×5
  Xie et al, 2012[27](#jah32000-bib-0027){ref-type="ref"}           China, 2007--2011           73 (38/35)                             51.1/50.4                        50.0/47.1             Elective valve surgery                                                                      Troponin I level at 6, 12, 24, 48 and 72 h                                                          Valve                           Yes            Yes                    UL, 3×5
  Young et al, 2012[13](#jah32000-bib-0013){ref-type="ref"}         New Zealand, 2010--2011     96 (48/48)                             65.5/64.4                        60.4/64.6             Double‐valve or triple‐valve surgery, mitral valve surgery, CABG                            Postoperative high‐sensitivity troponin T at 6 and 12 h and AKI                                     Mixed                           Yes            Yes                    UL, 3×5
  Lomivorotov et al, 2012[41](#jah32000-bib-0041){ref-type="ref"}   Russia 2010--2011           80 (40/40)                             56.6/58.1                        90.0/92.5             Adults undergoing CABG on CPB                                                               Postoperative hemodynamic markers and troponin I and CK‐MB at 6, 24, and 48 h                       CABG                            Yes            No                     UL, 3×5
  Meybohm et al, 2013[28](#jah32000-bib-0028){ref-type="ref"}       Germany 2009--2010          180 (90/90)                            70.0/68.0                        76.7/85.6             Age \>18 y undergoing cardiac surgery on CPB                                                Postoperative neurocognitive dysfunction at days 5 to 7                                             Mixed                           Yes            No                     UL, 4×5
  Thielmann et al, 2013[29](#jah32000-bib-0029){ref-type="ref"}     Germany 2008--2012          329 (162/167)                          68.2/69.1                        83.0/80.0             Adults with triple‐vessel disease undergoing primary, isolated, elective CABG on CPB        Perioperative myocardial injury reflected by AUC for troponin I                                     CABG                            Yes            Unknown                UL, 3×5
  Gallagher et al, 2015[30](#jah32000-bib-0030){ref-type="ref"}     UK, 2011--2012              86 (43/43)                             68.7/72.8                        76.7/83.7             Patients with chronic kidney disease undergoing CABG                                        Postoperative AKI within 48 h                                                                       Mixed                           Unknown        Yes                    UL, 3×5
  Ahmad et al, 2014[12](#jah32000-bib-0012){ref-type="ref"}         Pakistan, 2012--2013        67 (35/32)                             54.5/55.2                        77.1/78.1             Patients with class III angina and triple‐vessel disease                                    Postoperative CK‐MB levels at 1, 6, 12, and 24 h                                                    CABG                            Yes            Unknown                UL, 3×5
  Slagsvold et al, 2014[31](#jah32000-bib-0031){ref-type="ref"}     Norway, 2011                60 (30/30)                             64.0/68.0                        90.0/76.7             Urgent or elective first‐time CABG surgery                                                  Mitochondrial respiration in situ as assessed by left ventricular biopsy                            CABG                            Yes            Yes                    UL, 3×5
  Candilio et al, 2015[32](#jah32000-bib-0032){ref-type="ref"}      UK, 2010--2012              178 (89/89)                            65.0/66.0                        81.0/75.0             Adult patients undergoing CABG and/or valve surgery                                         Perioperative myocardial infarction, measured by 72‐h AUC hsTnT                                     Mixed                           Yes            No                     UL, 3×5
  Zarbock et al, 2015[11](#jah32000-bib-0011){ref-type="ref"}       Germany, 2013--2014         240 (120/120)                          70.1/70.6                        63.3/62.5             Adults at high risk for acute kidney injury undergoing cardiac surgery with CPB             Postoperative acute kidney injury at 72 h                                                           Mixed                           No             No                     UL, 3×5
  Pinaud et al, 2016[33](#jah32000-bib-0033){ref-type="ref"}        France, 2011--2012          99 (50/49)                             75.8/72.9                        54.0/48.9             Age \>18 y undergoing elective aortic valve replacement                                     Postoperative AUC troponin I at 72 h                                                                Valve                           Yes            No                     UL, 3×5
  Meybohm et al, 2015[16](#jah32000-bib-0016){ref-type="ref"}       Germany, 2011--2014         1385 (692/693)                         65.8/66.0                        73.4/75.0             Age \>18 y undergoing elective cardiac surgery requiring CPB                                Composite of death, MI, stroke or acute renal failure                                               Mixed                           Yes            No                     UL, 4×5
  Hausenloy et al, 2015[15](#jah32000-bib-0015){ref-type="ref"}     UK, 2010--2015              1612 (801/811)                         76.1/76.3                        70.4/72.7             Age \>18 y; additive EuroSCORE ≥5 undergoing on‐pump CABG (with or without valve surgery)   Composite of death from cardiovascular causes, nonfatal MI, coronary revascularization, or stroke   Mixed                           Yes            No                     UL, 4×5

AKI indicates acute kidney injury; AUC, area under the curve; CABG, coronary artery bypass grafting; CK‐MB, creatinine kinase, myocardial B fraction; CPB, cardiopulmonary bypass; EuroSCORE, European System for Cardiac Operative Risk Evaluation; hsTnT, high‐sensitivity troponin T; ICU, intensive care unit; K‐ATP, potassium‐ATP; LL, lower limb; LOS, length of stay; MI, myocardial infarction; RIPC, remote ischemic preconditioning; UK, United Kingdom; UL, upper limb; US, United States.

Of the 5262 patients included in the analysis, 2624 were randomized to RIPC and 2638 were randomized to a sham procedure. Baseline characteristics of the study populations showed that most patients were men (72.6%). The mean or median ages of patients ranged from 42.3 to 76.3 years. The majority of studies were double‐blinded, randomized, and had adequate descriptions of patient attrition. Study quality is summarized in Table [3](#jah32000-tbl-0003){ref-type="table-wrap"}.

###### 

Study Quality and Risk of Bias Using the GRADE Criteria[18](#jah32000-bib-0018){ref-type="ref"}

  Quality Assessment      No. of Patients     Effect                                                                                                                                        Quality                                                                                                                                       Importance                                                                                                                                                                                        
  ----------------------- ------------------- --------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------ ------------- ------ ------------------ ------------------ ---------------------- ---------------------------------------------- --------------- -----------
  All‐cause mortality                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  12                      Randomized trials   Serious[a](#jah32000-note-0006){ref-type="fn"} ^,^ [b](#jah32000-note-0007){ref-type="fn"}                                                    Serious[c](#jah32000-note-0008){ref-type="fn"} ^,^ [d](#jah32000-note-0009){ref-type="fn"}                                                    Not serious                                      Not serious   None   96/2098 (4.6%)     92/2112 (4.4%)     RR 0.98 (0.63--1.53)   1 fewer per 1000 (from 16 fewer to 23 more)    ⨁⨁◯◯ Low        CRITICAL
  Acute kidney injury                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  12                      Randomized trials   Serious[a](#jah32000-note-0006){ref-type="fn"} ^,^ [b](#jah32000-note-0007){ref-type="fn"}                                                    Not serious                                                                                                                                   Serious[e](#jah32000-note-0010){ref-type="fn"}   Not serious   None   516/2091 (24.7%)   577/2118 (27.2%)   RR 0.85 (0.69--1.03)   41 fewer per 1000 (from 8 more to 84 fewer)    ⨁⨁◯◯ Low        CRITICAL
  Myocardial infarction                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  6                       Randomized trials   Not serious                                                                                                                                   Not serious                                                                                                                                   Not serious                                      Not serious   None   237/1891 (12.5%)   282/1908 (14.8%)   RR 0.80 (0.61--1.04)   30 fewer per 1000 (from 6 more to 58 fewer)    ⨁⨁⨁⨁ High       IMPORTANT
  Stroke                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  6                       Randomized trials   Not serious                                                                                                                                   Serious[c](#jah32000-note-0008){ref-type="fn"}                                                                                                Not serious                                      Not serious   None   34/1864 (1.8%)     37/1880 (2.0%)     RR 0.94 (0.59--1.49)   1 fewer per 1000 (from 8 fewer to 10 more)     ⨁⨁⨁◯ Moderate   IMPORTANT
  ICU length of stay                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  12                      Randomized trials   Very serious[a](#jah32000-note-0006){ref-type="fn"} ^,^ [b](#jah32000-note-0007){ref-type="fn"} ^,^ [f](#jah32000-note-0011){ref-type="fn"}   Very serious[c](#jah32000-note-0008){ref-type="fn"} ^,^ [d](#jah32000-note-0009){ref-type="fn"} ^,^ [g](#jah32000-note-0012){ref-type="fn"}   Not serious                                      Not serious   None   1381               1396               ---                    SMD 0.004 SD more (0.11 fewer to 0.12 more)    ⨁◯◯◯ very low   IMPORTANT
  Hospital LOS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  13                      Randomized trials   Very serious[a](#jah32000-note-0006){ref-type="fn"} ^,^ [b](#jah32000-note-0007){ref-type="fn"} ^,^ [f](#jah32000-note-0011){ref-type="fn"}   Very serious[c](#jah32000-note-0008){ref-type="fn"} ^,^ [d](#jah32000-note-0009){ref-type="fn"} ^,^ [g](#jah32000-note-0012){ref-type="fn"}   Not serious                                      Not serious   None   559                567                ---                    SMD 0.005 SD fewer (0.12 fewer to 0.11 more)   ⨁◯◯◯ very low   IMPORTANT

GRADE indicates Grades of Recommendation, Assessment, Development, and Evaluation; ICU, intensive care unit; LOS, length of stay; RR, risk ratio; SMD, standardized mean difference. GRADE score quality is reflected by: high quality (at least 4 ⨁ overall), moderate quality (3 ⨁ ), low quality (2 ⨁ ), and very low quality (one ? or less)

Randomization methods not consistently described.

Multiple trials were not double‐blinded.

Direction of effect not consistent.

Point estimates varied widely.

Definition of outcome varied.

Patient attrition not described.

Significant statistical heterogeneity.

Quantitative Outcomes {#jah32000-sec-0010}
---------------------

Of the 188 deaths in the 4210 randomized patients undergoing cardiac surgery, 96 deaths occurred in the 2098 patients (4.6%) randomized to RIPC, whereas 92 deaths occurred in the 2112 patients (4.4%) randomized to a sham control procedure. The RR for mortality for RIPC versus sham was 0.987 (95% CI, 0.653--1.492; *P*=0.95 \[*I* ^*2*^=16%\]) (Figure [2](#jah32000-fig-0002){ref-type="fig"}A). AKI occurred in 516 of 2091 patients (24.7%) undergoing RIPC and in 577 of 2118 patients (27.2%) who underwent a sham procedure. The RR for AKI for RIPC versus sham procedure was 0.839 (95% CI, 0.703--1.001; *P*=0.052 \[*I* ^*2*^=41%\]) (Figure [2](#jah32000-fig-0002){ref-type="fig"}B). Postoperative MI occurred in 237 of 1891 patients (12.5%) randomized to RIPC and in 282 of 1908 patients (14.8%) randomized to a sham procedure. The RR for MI for RIPC versus sham was 0.809 (95% CI, 0.615--1.064; *P*=0.13 \[*I* ^*2*^=27%\]) (Figure [2](#jah32000-fig-0002){ref-type="fig"}C). Postoperative CVA was diagnosed in 34 of 1864 patients (1.82%) who underwent RIPC and in 37 of 1880 patients (1.97%) who underwent a sham procedure. The RR for CVA for RIPC versus sham was 0.939 (95% CI, 0.592--1.489; *P*=0.79 \[*I* ^*2*^=0%\]) (Figure [2](#jah32000-fig-0002){ref-type="fig"}D). The standardized difference in mean ICU LOS was 0.010 days (95% CI, −0.116 to 0.137; *P*=0.87 \[*I* ^*2*^=41%\]) between the 1381 patients in the RIPC group and the 1396 patients in the sham control group (Figure [2](#jah32000-fig-0002){ref-type="fig"}E). Similarly, the standardized difference in mean hospital LOS was 0.026 days (95% CI, −0.091 to 0.143; *P*=0.67 \[*I* ^*2*^=0%\]) for the 559 patients undergoing RIPC versus 567 patients having a sham procedure (Figure [2](#jah32000-fig-0002){ref-type="fig"}F). Summarized quantitative data for the entire sample can be seen in Table [3](#jah32000-tbl-0003){ref-type="table-wrap"}.

![Comparison of outcomes between remote ischemic preconditioning (RIPC) and sham procedure. A, All‐cause mortality. B, Acute kidney injury. C, Myocardial infarction. D, Stroke. E, Intensive care unit length of stay. F, Hospital length of stay. The sizes of the squares representing the point estimates for each study are proportional to the weight of the study. Diamonds indicate the overall risk ratio (RR) or standardized mean difference and 95% CIs for the outcome of interest.](JAH3-6-e004666-g002){#jah32000-fig-0002}

Subgroup Analyses, Sensitivity Analyses, and Publication Bias {#jah32000-sec-0011}
-------------------------------------------------------------

Subgroup analysis showed no differences in outcomes when compared by the use of K‐ATP antagonists (results not shown). In the subgroup of studies of patients who did not receive propofol, we observed that most of these patients were men (60.3%) and the mean or median age ranged from 57.0 to 70.6 years. In this propofol‐free subgroup, 71 of 217 patients (32.7%) who underwent RIPC developed AKI compared with 103 of 217 patients (47.5%) treated with a sham procedure. The RR for AKI was 0.700 (95% CI, 0.527--0.930; *P*=0.014) for RIPC versus sham. In studies of patients who received propofol, 445 of 1874 (23.7%) who received RIPC developed AKI compared with 474 of 1901 (24.9%) who underwent a sham procedure. The RR for AKI was 0.928 (95% CI, 0.781--1.102; *P*=0.39) for RIPC versus sham (Figure [3](#jah32000-fig-0003){ref-type="fig"}). Summarized quantitative data for these subgroups can be seen in Table [4](#jah32000-tbl-0004){ref-type="table-wrap"}. There was no significant interaction between the two subgroups (*P*=0.098). Additionally, there were no differences in the effect of RIPC on development of stage I, II, or III AKI, and there was no difference in the effect of RIPC on the development of severe AKI, defined as stage II or III AKI (results not shown).

![Subgroup analysis of cardiac surgeries performed with and without propofol anesthesia. The sizes of the squares representing the point estimates for each study are proportional to the weight of the study. Diamonds indicate the overall risk ratio (RR) and 95% CIs. RIPC indicates remote ischemic preconditioning.](JAH3-6-e004666-g003){#jah32000-fig-0003}

###### 

Subgroup Analysis of Perioperative Propofol Use

  No. (RIPC)                                                                                                                                                                                                                                                                                                                                                                                                           AKI (RIPC)    No. (Sham)   AKI (Sham)    RR (95% CI)            *P* Value
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------- ------------ ------------- ---------------------- -----------
  Propofol used (N=9 trials)[13](#jah32000-bib-0013){ref-type="ref"}, [15](#jah32000-bib-0015){ref-type="ref"}, [16](#jah32000-bib-0016){ref-type="ref"}, [20](#jah32000-bib-0020){ref-type="ref"}, [21](#jah32000-bib-0021){ref-type="ref"}, [28](#jah32000-bib-0028){ref-type="ref"}, [30](#jah32000-bib-0030){ref-type="ref"}, [32](#jah32000-bib-0032){ref-type="ref"}, [33](#jah32000-bib-0033){ref-type="ref"}                                                                   
  1874                                                                                                                                                                                                                                                                                                                                                                                                                 445 (23.7%)   1901         474 (24.9%)   0.928 (0.781--1.102)   0.39
  Propofol not used (N=3 trials)[3](#jah32000-bib-0003){ref-type="ref"}, [11](#jah32000-bib-0011){ref-type="ref"}, [25](#jah32000-bib-0025){ref-type="ref"}                                                                                                                                                                                                                                                                                                                            
  217                                                                                                                                                                                                                                                                                                                                                                                                                  71 (32.7%)    217          103 (47.5%)   0.700 (0.527--0.930)   0.014

AKI indicates acute kidney injury; RIPC, remote ischemic preconditioning; RR, risk ratio.

Sensitivity analyses showed no significant differences in outcomes when results were compared by study quality (high versus low), type of surgery performed (CABG, valve, or mixed), severity of illness (based on additive EuroSCORE), or duration or site of RIPC (results not shown). Visual inspection of the funnel plots suggested possible publication bias (Figure [4](#jah32000-fig-0004){ref-type="fig"}). This was further analyzed using the trim and fill method. The RR of AKI of 0.839 (95% CI, 0.702--1.001) was unchanged by the trim and fill method, suggesting no publication bias. This was confirmed by the Egger\'s test, which indicated lack of publication bias (*P*=0.055).

![Assessment of publication bias. This funnel plot is a plot of a measure of study size on the vertical axis as a function of effect size on the horizontal axis for acute kidney injury. Large studies appear toward the top of the graph and tend to cluster near the mean effect size. Smaller studies appear toward the bottom of the graph and (since there is more sampling variation in effect size estimates in the smaller studies) will be dispersed across a range of values. In the absence of publication bias, the studies, represented by circles, are distributed symmetrically about the combined effect size. The dashed diamond appearing below the *x* axis represents the summary effect.](JAH3-6-e004666-g004){#jah32000-fig-0004}

In addition, sensitivity analyses to assess potential effects of qualitative differences on study design and patient selection showed that exclusion of any one trial from analysis of mortality, AKI, MI, CVA, ICU LOS, and hospital LOS did not change the overall findings (data not shown).

Discussion {#jah32000-sec-0012}
==========

In this meta‐analysis of 5262 patients undergoing RIPC for cardiac surgery with cardiopulmonary bypass, we found that RIPC conferred no clinical benefit. The intervention failed to reduce the incidence of all‐cause mortality, MI, CVA, and ICU or hospital LOS. There was a strong trend towards reduction of AKI in patients who underwent RIPC.

Previous meta‐analyses have also failed to demonstrate clinical benefit of RIPC.[42](#jah32000-bib-0042){ref-type="ref"}, [43](#jah32000-bib-0043){ref-type="ref"} However, two aspects of this meta‐analysis differentiate it from prior studies. First, this analysis includes two recent, large, high‐quality RCTs of RIPC in patients undergoing cardiac surgery not included in previous meta‐analyses.[15](#jah32000-bib-0015){ref-type="ref"}, [16](#jah32000-bib-0016){ref-type="ref"} The inclusion of these trials increased the study population 2‐fold. Second, as far as we are aware, this is the first meta‐analysis to evaluate outcomes as a function of propofol and K‐ATP antagonist use.

Although the mechanisms of RIPC have not been fully elucidated, many believe there are components of both humoral and sensory‐neuronal pathways that confer organ protection.[44](#jah32000-bib-0044){ref-type="ref"} The neuronal pathway was first described by Jones et al,[45](#jah32000-bib-0045){ref-type="ref"} who demonstrated that myocardial protection could be produced through activation of sensory C fibers by an abdominal incision in mice. Furthermore, transection of the spinal cord and blockade of sensory C fibers by lidocaine abrogated the benefit of preconditioning, suggesting neuronal signal transmission. Similarly, propofol may disrupt mediators of the neuronal pathway and diminish the clinical benefits of RIPC when compared with isoflurane anesthesia.[14](#jah32000-bib-0014){ref-type="ref"}, [46](#jah32000-bib-0046){ref-type="ref"} Other investigators have suggested propofol itself may be protective and any incremental benefits of RIPC are too small to be detected.[47](#jah32000-bib-0047){ref-type="ref"} Our analysis is congruent with these theories, as we observed a highly significant reduction in AKI in the subgroup of patients who did not receive propofol, despite no benefit in the overall cohort.

In addition to the neuronal pathway, humoral‐mediated pathways have also been described. After Huffman et al[48](#jah32000-bib-0048){ref-type="ref"} demonstrated that transfer of serum from preconditioned to recipient rats prior to an induced MI conferred cardiac protection, the mediators of this pathway were explored. Adenosine and bradykinin, among other mediators, have been shown to induce preconditioning of myocytes, thought to be via the activation of the K‐ATP channel pathway.[44](#jah32000-bib-0044){ref-type="ref"}, [49](#jah32000-bib-0049){ref-type="ref"}, [50](#jah32000-bib-0050){ref-type="ref"} Loukogeorgakis et al[51](#jah32000-bib-0051){ref-type="ref"} implicated the K‐ATP pathway in IPC‐mediated endothelial protection by demonstrating abolition of the protective effect after administration of glibenclamide, a K‐ATP antagonist. In our subgroup analysis, after removal of studies that included patients treated with K‐ATP antagonists, clinical benefit of RIPC was still not observed.

Study Limitations {#jah32000-sec-0013}
-----------------

The results of this meta‐analysis should be interpreted with consideration of its limitations. First, the majority of trials included in the review were single‐center studies with varying inclusion and exclusion criteria. Second, definitions for outcomes and duration of follow‐up differed between included trials. Third, because we assumed that all patients in a given trial either did or did not receive propofol, a portion of patients within individual trials may have been miscategorized. Additionally, variability in RIPC protocols may have led to heterogeneity in the analysis. Finally, data were extracted only from RCTs and may not be representative of patients treated in usual practice.

Conclusions {#jah32000-sec-0014}
===========

RIPC does not prevent morbidity or mortality in patients undergoing cardiac surgery with cardiopulmonary bypass. In the subgroup of studies in which propofol was not used, a reduction in AKI was seen, suggesting that propofol may interact with the protective effects of RIPC. To evaluate the independent effect of RIPC on outcomes, future studies on RIPC should be performed in the absence of propofol anesthesia.

Disclosures {#jah32000-sec-0015}
===========

None.
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